TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
01/26/2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
|
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
01/11/2023
The Grieving Brain: The Science of Love and Loss
Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at the…
|
12/23/2022
AIM at Melanoma Earns a Four-Star Rating From Charity Navigator
December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
|
12/19/2022
The Future of Melanoma Treatment: 2023 and Beyond
Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
|
12/08/2022
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
|
|
11/16/2022
How’s it Growing?
AIM at Melanoma is honored to have been selected by the Matthew Hill Foundation to be a benefitting charity in…
|
11/16/2022
President’s Letter | November 2022
From the Desk of Samantha Guild November is the month to prioritize our gratitude, and I never tire of this…
|
11/16/2022
The Importance of Having a Will
It started with a 13-year melanoma survivor letting us know that he had put us in his will. Jeff Berg,…
|
11/16/2022
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Background—Immunotherapy of melanoma The explosion of immunotherapy over the past decade has revolutionized the…
|
Recent Posts
Feb. 21, 2025
Inheriting Cancer Risk Factors
Feb. 17, 2025
The Heart of Care: Palliative Care and Oncology Social Work
Feb. 14, 2025
Men and Women and Melanoma: Who’s Winning the Battle?
Feb. 06, 2025
Genetic Testing Performed in Melanoma
Jan. 21, 2025